Sun Pharma’s U.S. Arm Taro’s Growth In Q3 Hurt By Covid-19: Prabhudas Lilladher 

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Prabhudas Lilladher Report

Sun Pharmaceutical Industries Ltd.’s U.S. Arm Taro’s revenue was sequentially flattish while gross profit and gross margin were lower QoQ indicating continual price erosion, unfavorable product mix and impact from Covid-19.

We expect sales growth to be muted and quarterly revenue to remain stable in the range of $140-150 million.

Key event for Taro in the near-term would be utilisation of $1.55 billion cash and cash equivalent for acquisition of specialty products, as its own products pipeline have only 17 abbreviated new drug applications pending with U.S. Food and Drug Administration.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.